Effect of propafenone on left ventricular ejection fraction.

Area of Science:

• Cardiology
• Pharmacology

Background:

• Propafenone is an antiarrhythmic drug.
• Left ventricular ejection fraction (LVEF) is a key measure of cardiac function.

Purpose of the Study:

• To investigate the effects of propafenone on ejection fraction (EF) in patients with and without left ventricular (LV) dysfunction.
• To assess the influence of digoxin therapy on propafenone's cardiac effects.

Main Methods:

• Two groups of patients were studied: Group A (no LV dysfunction, no digoxin) and Group B (LV dysfunction, on digoxin).
• Oral propafenone was administered at different daily dosages (879 mg for Group A, 600 mg for Group B).
• Ejection fraction was measured using radionuclide angiography.

Main Results:

• In Group A, propafenone (879 mg/day) significantly decreased resting LVEF (52% to 48%, p<0.05).
• In Group B, propafenone (600 mg/day) did not significantly alter LVEF.
• No clinically significant effects on cardiac compensation were observed in either group.

Conclusions:

• Propafenone may exert a negative inotropic effect, potentially related to dosage.
• Digoxin therapy may attenuate the negative inotropic effects of propafenone.
• Further studies are required to fully elucidate propafenone's impact on LV function and its interaction with digoxin.